LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 98

Search options

  1. Article ; Online: A single inhibitor for all KRAS mutations.

    Corcoran, Ryan B

    Nature cancer

    2023  Volume 4, Issue 8, Page(s) 1060–1062

    Language English
    Publishing date 2023-08-24
    Publishing country England
    Document type Journal Article
    ISSN 2662-1347
    ISSN (online) 2662-1347
    DOI 10.1038/s43018-023-00615-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy.

    Corcoran, Ryan B

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 41, Issue 3, Page(s) 436–438

    MeSH term(s) Humans ; ErbB Receptors/genetics ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Cell Line, Tumor ; Drug Resistance, Neoplasm
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2022-12-08
    Publishing country United States
    Document type Editorial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.01922
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Liquid biopsy versus tumor biopsy for clinical-trial recruitment.

    Corcoran, Ryan B

    Nature medicine

    2020  Volume 26, Issue 12, Page(s) 1815–1816

    MeSH term(s) Biopsy ; Circulating Tumor DNA ; Gastrointestinal Neoplasms ; Humans ; Japan ; Liquid Biopsy
    Chemical Substances Circulating Tumor DNA
    Language English
    Publishing date 2020-11-23
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-020-01169-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response.

    Parikh, Aparna R / Corcoran, Ryan B

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2021  Volume 27, Issue 23, Page(s) 6614–6615

    MeSH term(s) Biomarkers, Tumor/genetics ; Circulating Tumor DNA/genetics ; Humans
    Chemical Substances Biomarkers, Tumor ; Circulating Tumor DNA
    Language English
    Publishing date 2021-11-17
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-21-3306
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction?

    Corcoran, Ryan B / Grothey, Axel

    JAMA oncology

    2020  Volume 6, Issue 6, Page(s) 823–824

    MeSH term(s) Canada ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; DNA Mismatch Repair/genetics ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Microsatellite Repeats
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2020-05-07
    Publishing country United States
    Document type Editorial ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.0504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: New therapeutic strategies for BRAF mutant colorectal cancers.

    Corcoran, Ryan B

    Journal of gastrointestinal oncology

    2015  Volume 6, Issue 6, Page(s) 650–659

    Abstract: Oncogenic BRAF mutations are found in ~10% of colorectal cancers (CRCs) and predict poor prognosis. Although BRAF inhibitors have demonstrated striking efficacy in BRAF mutant melanomas, BRAF inhibitor monotherapy is ineffective in BRAF mutant CRC. Over ... ...

    Abstract Oncogenic BRAF mutations are found in ~10% of colorectal cancers (CRCs) and predict poor prognosis. Although BRAF inhibitors have demonstrated striking efficacy in BRAF mutant melanomas, BRAF inhibitor monotherapy is ineffective in BRAF mutant CRC. Over the past few years, studies have begun to define the molecular mechanisms underlying the relative resistance of BRAF mutant CRC to BRAF inhibitors, leading to the development of novel therapeutic strategies that are showing promising clinical activity in initial clinical trials. Our current understanding of the mechanisms of BRAF inhibitor resistance in BRAF mutant CRC and the therapeutic approaches currently in clinical trials for BRAF mutant CRC are reviewed herein.
    Language English
    Publishing date 2015-12-22
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2594644-4
    ISSN 2219-679X ; 2078-6891
    ISSN (online) 2219-679X
    ISSN 2078-6891
    DOI 10.3978/j.issn.2078-6891.2015.076
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Targeting Alterations in the RAF-MEK Pathway.

    Yaeger, Rona / Corcoran, Ryan B

    Cancer discovery

    2019  Volume 9, Issue 3, Page(s) 329–341

    Abstract: The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer. Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in downstream components of the pathway, including the RAF and MEK genes, offer ... ...

    Abstract The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer. Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in downstream components of the pathway, including the RAF and MEK genes, offer promising therapeutic opportunities. In addition to BRAF
    MeSH term(s) Animals ; Humans ; MAP Kinase Kinase 1/antagonists & inhibitors ; MAP Kinase Kinase 1/metabolism ; MAP Kinase Signaling System/drug effects ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Prognosis ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; raf Kinases/antagonists & inhibitors ; raf Kinases/metabolism
    Chemical Substances Protein Kinase Inhibitors ; raf Kinases (EC 2.7.11.1) ; MAP Kinase Kinase 1 (EC 2.7.12.2)
    Language English
    Publishing date 2019-02-15
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-18-1321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Therapeutic strategies to target RAS-mutant cancers.

    Ryan, Meagan B / Corcoran, Ryan B

    Nature reviews. Clinical oncology

    2018  Volume 15, Issue 11, Page(s) 709–720

    Abstract: RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, ... ...

    Abstract RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors. In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising strategies being tested in clinical trials at different stages of completion. Important advances have also been made in approaches designed to indirectly target RAS by improving inhibition of RAS effectors, exploiting synthetic lethal interactions or metabolic dependencies, using therapeutic combination strategies or harnessing the immune system. In this Review, we describe historical and ongoing efforts to target RAS-mutant cancers and outline the current therapeutic landscape in the collective quest to overcome the effects of this crucial oncogene.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Humans ; Molecular Targeted Therapy ; Mutation ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Signal Transduction/drug effects ; ras Proteins/antagonists & inhibitors ; ras Proteins/genetics
    Chemical Substances Antineoplastic Agents ; ras Proteins (EC 3.6.5.2)
    Language English
    Publishing date 2018-10-01
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-018-0105-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Application of Cell-free DNA Analysis to Cancer Treatment.

    Corcoran, Ryan B / Chabner, Bruce A

    The New England journal of medicine

    2018  Volume 379, Issue 18, Page(s) 1754–1765

    MeSH term(s) Circulating Tumor DNA/analysis ; Circulating Tumor DNA/blood ; DNA, Neoplasm/analysis ; Humans ; Liquid Biopsy/methods ; Mutation ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/therapy ; Standard of Care
    Chemical Substances Circulating Tumor DNA ; DNA, Neoplasm
    Language English
    Publishing date 2018-10-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMra1706174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Cell-free DNA Analysis in Cancer.

    Corcoran, Ryan B / Chabner, Bruce A

    The New England journal of medicine

    2018  Volume 380, Issue 5, Page(s) 501–502

    MeSH term(s) Biomarkers, Tumor ; Cell-Free Nucleic Acids ; Humans ; Neoplasms
    Chemical Substances Biomarkers, Tumor ; Cell-Free Nucleic Acids
    Language English
    Publishing date 2018-11-28
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1816154
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top